Technical Report Geriatrics Preventive Medicine
30-day readmission after tranexamic acid in patients with heart failure: A cross-sectional survey

30-day readmission after tranexamic acid in patients with heart failure: A cross-sectional survey

Authors

Sarah Andersen

Sarah Andersen

Mayo Clinic, Belarus

Layla Osei

Layla Osei

Aga Khan University Hospital, Anguilla

Aisha Mueller

Aisha Mueller

American University of Beirut Medical Center, Gabon

Omar Rahman

Omar Rahman

Charité Berlin, Dominica

Corresponding
Daniel Lindqvist

Daniel Lindqvist

Hamad Medical Corporation, Democratic Republic of the Congo

Published

November 21, 2023

Paper ID

PAP-000102

Status

Published

DOI

10.65712/tmj.test000360

30-day readmission after tranexamic acid in patients with heart failure: A cross-sectional survey

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around tranexamic acid varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Guidelines make only a weak recommendation on tranexamic acid. Practice around tranexamic acid varies widely between centres. 30-day readmission remains a leading cause of avoidable harm among patients with heart failure.

The cost of 30-day readmission to health systems is substantial. 30-day readmission remains a leading cause of avoidable harm among patients with heart failure. Practice around tranexamic acid varies widely between centres.

The cost of 30-day readmission to health systems is substantial. Guidelines make only a weak recommendation on tranexamic acid.

Discussion

Strengths include the sample size and blinded outcome assessment. These findings suggest that tranexamic acid is associated with better 30-day readmission in patients with heart failure.

Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.

Conclusions

Tranexamic acid should be considered for patients with heart failure to improve 30-day readmission.

References

1. Okafor V, Okafor F, et al. Home-based cardiac rehabilitation and glycaemic control. JAMA. 2019;166(8):404-1041.

2. Andersen E, Patel P, et al. Prone positioning and in-hospital mortality. BMJ. 2019;391(12):551-1757.

3. Okafor D, Silva M, et al. Early enteral nutrition and post-operative delirium. Crit Care Med. 2023;372(6):342-1026.

4. Nakamura C, Haddad O, et al. Tranexamic acid and chronic pain scores. BMC Med. 2009;256(8):32-1641.

5. Volkov R, Costa U, et al. Tranexamic acid and 30-day readmission. Eur Heart J. 2021;366(8):26-1561.

6. Farouk F, Herrera T, et al. Continuous glucose monitoring and health-related quality of life. BMC Med. 2023;128(6):719-1220.

7. Patel M, Herrera Y, et al. Tranexamic acid and surgical site infection. Crit Care Med. 2017;249(3):48-1036.

8. Costa P, Patel S, et al. Pharmacist-led medication review and patient satisfaction. Diabetes Care. 2021;296(2):321-1162.

9. Larsen R, Moreau H, et al. Vitamin D supplementation and 30-day readmission. Ann Intern Med. 2014;282(1):806-1016.

Appendices

Ethics approval: IRB-1097.

Materials and Methods

Eligible participants were patients with heart failure.

Missing data were handled with multiple imputation. Eligible participants were patients with heart failure.

Results

3492 participants were included (median age 38 years). Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.55 (95% CI 0.30 to 0.78).

GroupnEvents
Female89566
Male61862
Age < 6510773
Female38196
Intervention50277
TABLE 1: Subgroup analysis
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Distribution of 30-day readmission
Shown for patients with heart failure; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Forest plot of 30-day readmission
Shown for patients with heart failure; error bars are 95% confidence intervals.

The adjusted odds ratio was 0.55 (95% CI 0.26 to 0.80). The adjusted odds ratio was 0.89 (95% CI 0.34 to 0.62). Effects were consistent across prespecified subgroups.